Search

Your search keyword '"Krupp, Lauren B"' showing total 440 results
Start Over Author "Krupp, Lauren B"
440 results on '"Krupp, Lauren B"'

3. Multiple Sclerosis in Children

Author

Tyshkov, Charles D., Charvet, Leigh Elkins, Krupp, Lauren B., Tarsy, Daniel, Series Editor, Rizvi, Syed A., editor, Cahill, Jonathan F., editor, and Coyle, Patricia K., editor

Published
2020
Full Text
View/download PDF

7. Relapsing White Matter Disease and Subclinical Optic Neuropathy

Author

O'Neill, Kimberly A., primary, Dugue, Andrew, additional, Abreu, Nicolas J., additional, Balcer, Laura J., additional, Branche, Marc, additional, Galetta, Steven, additional, Graves, Jennifer, additional, Kister, Ilya, additional, Magro, Cynthia, additional, Miller, Claire, additional, Newsome, Scott D., additional, Pappas, John, additional, Rucker, Janet, additional, Steigerwald, Connolly, additional, William, Christopher M., additional, Zamvil, Scott S., additional, Grossman, Scott N., additional, and Krupp, Lauren B., additional

Published
2024
Full Text
View/download PDF

8. Genetic predictors of relapse rate in pediatric MS

Author

Graves, Jennifer S, Barcellos, Lisa F, Shao, Xiaorong, Noble, Janelle, Mowry, Ellen M, Quach, Hong, Belman, Anita, Casper, T Charles, Krupp, Lauren B, Waubant, Emmanuelle, and Centers, on behalf of the US Network of Pediatric MS

Subjects
Biomedical and Clinical Sciences, Neurosciences, Clinical Sciences, Neurodegenerative, Clinical Research, Multiple Sclerosis, Genetics, Autoimmune Disease, Pediatric, Brain Disorders, Genetic Testing, Prevention, Human Genome, Aetiology, 2.1 Biological and endogenous factors, Adolescent, Age of Onset, Calcitriol, Child, Female, Follow-Up Studies, Genotyping Techniques, HLA-DRB1 Chains, Humans, Male, Recurrence, Sex Factors, multiple sclerosis, relapsing/remitting, outcome measurement, vitamin D, U.S. Network of Pediatric MS Centers, Neurology & Neurosurgery, Clinical sciences, Biological psychology
Abstract

BackgroundGenetic ancestry, sex, and individual alleles have been associated with multiple sclerosis (MS) susceptibility.ObjectiveTo determine whether established risk factors for disease onset are associated with relapse rate in pediatric MS.MethodsWhole-genome genotyping was performed for 181 MS or high-risk clinically isolated syndrome patients from two pediatric MS centers. Relapses and disease-modifying therapies were recorded as part of continued follow-up. Participants were characterized for 25-hydroxyvitamin D serum status. Ancestral estimates (STRUCTURE v2.3.1), human leukocyte antigen (HLA)-DRB1*15 carrier status (direct sequencing), sex, and a genetic risk score (GRS) of 110 non-HLA susceptibility single-nucleotide polymorphisms (SNPs) were evaluated for association with relapse rate with Cox and negative binomial regression models.ResultsOver 622 patient-years, 408 relapses were captured. Girls had greater relapse rate than boys (incident rate ratio (IRR) = 1.40, 95% confidence interval (CI) = 1.04-1.87, p = 0.026). Participants were genetically diverse; ~40% (N = 75) had

Published
2016

9. A case-control study of dietary salt intake in pediatric-onset multiple sclerosis

Author

McDonald, Jamie, Graves, Jennifer, Waldman, Amy, Lotze, Timothy, Schreiner, Teri, Belman, Anita, Greenberg, Benjamin, Weinstock-Guttman, Bianca, Aaen, Gregory, Tillema, Jan-Mendelt, Hart, Janace, Lulu, Sabeen, Ness, Jayne, Harris, Yolanda, Rubin, Jennifer, Candee, Meghan, Krupp, Lauren B, Gorman, Mark, Benson, Leslie, Rodriguez, Moses, Chitnis, Tanuja, Mar, Soe, Barcellos, Lisa F, Laraia, Barbara, Rose, John, Roalstad, Shelly, Simmons, Timothy, Casper, T Charles, and Waubant, Emmanuelle

Subjects
Biomedical and Clinical Sciences, Nutrition and Dietetics, Nutrition, Brain Disorders, Prevention, Neurosciences, Pediatric, Neurodegenerative, Autoimmune Disease, Multiple Sclerosis, Clinical Research, Neurological, Adolescent, Age of Onset, Case-Control Studies, Disease Susceptibility, Feeding Behavior, Female, Humans, Male, Multiple Sclerosis, Relapsing-Remitting, Sodium Chloride, Dietary, United States, Multiple sclerosis, Epidemiology, Salt, Dietary factors, Susceptibility
Abstract

BackgroundHigh salt intake may be associated with pro-inflammatory changes in the immune response, and increased clinical and MRI activity in adults with relapsing-remitting multiple sclerosis.ObjectiveWe sought to determine if dietary salt intake is associated with pediatric-onset MS risk in a multicenter, case-control study.MethodsPediatric-onset CIS/MS cases within four years of onset and controls less than 22 years old recruited from 14 pediatric-MS centers were studied. Dietary sodium intake was assessed using the validated Block Kids Food Screener (NutritionQuest). Sodium intake, excess sodium, and sodium terciles were compared between cases and controls. Logistic regression models were adjusted for age, gender, ethnicity, body mass index, and socioeconomic status.ResultsAmong 170 cases (mean age=15.2±3.5) and 331 controls (mean age=14.0±3.7), no significant difference in unadjusted mean sodium intake was found between cases (2044mg/d) and controls (2030mg/d, p=0.99). The proportion of subjects consuming excess sodium, based on the adequate intake for age and gender, was similar between cases and controls (65% versus 69%, p=0.34). There were no increased odds of higher sodium intake among cases as compared to controls (for each 100mg/d increase in sodium, OR=1.00, 95% CI 0.98, 1.02; p=0.93, for excess sodium intake, OR=1.05, 95% CI 0.67, 1.64; p=0.84).ConclusionsOur results show no strong association between dietary salt intake and pediatric-onset MS risk, suggesting that salt intake may not play a prominent role in susceptibility to MS in children.

Published
2016

10. Lyme Disease

Author

Halperin, John, Krupp, Lauren B., Melville, Patricia, Kreutzer, Jeffrey S., editor, DeLuca, John, editor, and Caplan, Bruce, editor

Published
2018
Full Text
View/download PDF

11. Agreement Between Published Reference Resources for Neurofilament Light Chain Levels in People With Multiple Sclerosis

Author

Sotirchos, Elias S, primary, Hu, Chen, additional, Smith, Matthew D, additional, Lord, Hannah-Noelle, additional, DuVal, Anna L, additional, Arrambide, Georgina, additional, Montalban, Xavier, additional, Akgün, Katja, additional, Ziemssen, Tjalf, additional, Naismith, Robert T, additional, Hersh, Carrie M, additional, Hyland, Megan, additional, Krupp, Lauren B, additional, Nicholas, Jacqueline A, additional, Bermel, Robert A, additional, Mowry, Ellen M, additional, Calabresi, Peter A, additional, and Fitzgerald, Kathryn C, additional

Published
2023
Full Text
View/download PDF

13. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

Author

Achiron, Anat, Achtnichts, Lutz, Agan, Kadriye, Akman-Demir, Gulsen, Allen, Alison B, Antel, Jack P, Antiguedad, Alfredo Rodriguez, Apperson, Michelle, Applebee, Angela M, Ayuso, Guillermo Izquierdo, Baba, Masayuki, Bajenaru, Ovidiu, Balasa, Rodica, Balci, Belgin Petek, Barnett, Michael, Bass, Ann, Becker, Veit U, Bejinariu, Mihaela, Bergh, Florian Then, Bergmann, Arnfin, Bernitsas, Evanthia, Berthele, Achim, Bhan, Virender, Bischof, Felix, Bjork, Randall John, Blevins, Gregg, Boehringer, Matthias, Boerner, Thomas, Bonek, Robert, Bowen, James D, Bowling, Allen, Boyko, Alexey N, Boz, Cavit, Bracknies, Vera, Braune, Stefan, Brescia Morra, Vincenzo, Brochet, Bruno, Brola, Waldemar, Brownstone, Paul Kenneth, Brozman, Miroslav, Brunet, Donald, Buraga, Ioan, Burnett, Margaret, Buttmann, Mathias, Butzkueven, Helmut, Cahill, Jonathan, Calkwood, Jonathan C, Camu, William, Cascione, Mark, Castelnovo, Giovani, Centonze, Diego, Cerqueira, Joao, Chan, Andrew, Cimprichova, Andrea, Cohan, Stanley, Comi, Giancarlo, Conway, Jill, Cooper, Joanna A, Corboy, John, Correale, Jorge, Costell, Brian, Cottrell, David A, Coyle, Patricia K, Craner, Matthew, Cui, Liying, Cunha, Luis, Czlonkowska, Anna, da Silva, Ana Martins, de Sa, Joao, de Seze, Jérôme, Debouverie, Marc, Debruyne, Jan, Decoo, Danny, Defer, Gilles, Derfuss, Tobias, Deri, Norma H, Dihenia, Bhupesh, Dioszeghy, Peter, Donath, Vladimir, Dubois, Benedicte, Duddy, Martin, Duquette, Pierre, Edan, Gilles, Efendi, Husnu, Elias, Stanton, Emrich, Peter J, Estruch, Bonaventura Casanova, Evdoshenko, Evgeniy P, Faiss, Juergen, Fedyanin, Alexander S, Feneberg, Wolfgang, Fermont, Jiske, Fernandez, Oscar Fernandez, Ferrer, Francisco Coret, Fink, Katharina, Ford, Helen, Ford, Corey, Francia, Ada, Freedman, Mark, Frishberg, Benjamin, Galgani, Simonetta, Garmany, George P, Gehring, Klaus, Gitt, Jeffrey, Gobbi, Claudio, Goldstick, Lawrence P, Gonzalez, Rafael Arroyo, Grandmaison, Francois, Grigoriadis, Nikolaos, Grigorova, Olga, Grimaldi, Luigi Maria Edoardo, Gross, Jeffrey, Gross-Paju, Katrin, Gudesblatt, Mark, Guillaume, Daniel, Haas, Judith, Hancinova, Viera, Hancu, Anca, Hardiman, Orla, Harmjanz, Arndt, Heidenreich, Fedor R, Hengstman, G J D, Herbert, Joseph, Herring, Mark, Hodgkinson, Suzanne, Hoffmann, Olaf M, Hofmann, Werner E, Honeycutt, William D, Hua, Le Hanh, Huang, Dehui, Huang, Yining, Huang, DeRen, Hupperts, Raymond, Imre, Piroska, Jacobs, Alan Keith, Jakab, Gabor, Jasinska, Elzbieta, Kaida, Kenichi, Kalnina, Jolanta, Kaprelyan, Ara, Karelis, Guntis, Karussis, Dimitrios, Katz, Amos, Khabirov, Farit A, Khatri, Bhupendra, Kimura, Takashi, Kister, Ilya, Kizlaitiene, Rasa, Klimova, Eleonora, Koehler, Juergen, Komatineni, Aparna, Kornhuber, Anselm, Kovacs, Krisztina, Koves, Agnes, Kozubski, Wojciech, Krastev, Georgi, Krupp, Lauren B, Kurca, Egon, Lassek, Christoph, Laureys, Guy, Lee, Liesly, Lensch, Eckart, Leutmezer, Fritz, Li, Hongzeng, Linker, Ralf A, Linnebank, Michael, Liskova, Petra, Llanera, Cristina, Lu, Jiahong, Lutterotti, Andreas, Lycke, Jan, Macdonell, Richard, Maciejowski, Maciej, Maeurer, Mathias, Magzhanov, Rim V, Maida, Eva-Maria, Malciene, Lina, Mao-Draayer, Yang, Marfia, Girolama Alessandra, Markowitz, Clyde, Mastorodimos, Vasileios, Matyas, Klotild, Meca-Lallana, Jose, Merino, Juan Antonio Garcia, Mihetiu, Ioan Gheorghe, Milanov, Ivan, Miller, Aaron E, Millers, Andrejs, Mirabella, Massimiliano, Mizuno, Masanori, Montalban, Xavier, Montoya, Lilina, Mori, Masahiro, Mueller, Stefanie, Nakahara, Jin, Nakatsuji, Yuji, Newsome, Scott, Nicholas, Richard, Nielsen, A Scott, Nikfekr, Esmaeil, Nocentini, Ugo, Nohara, Chiyoko, Nomura, Kyoichi, Odinak, Miroslav M, Olsson, Tomas, van Oosten, B W, Oreja-Guevara, Celia, Oschmann, Patrick, Overell, James, Pachner, Andrew, Panczel, Gyula, Pandolfo, Massimo, Papeix, Caroline, Patrucco, Liliana, Pelletier, Jean, Piedrabuena, Raul, Pless, Misha, Polzer, Udo, Pozsegovits, Krisztian, Rastenyte, Daiva, Rauer, Sebastian, Reifschneider, Gerd, Rey, Roberto, Rizvi, Syed A, Robertson, Derrick, Rodriguez, Jose Martinez, Rog, David, Roshanisefat, Homayoun, Rowe, Vernon, Rozsa, Csilla, Rubin, Susan, Rusek, Stanislaw, Saccà, Francesco, Saida, Takahiko, Salgado, Antonio Vasco, Sanchez, Victoria Eugenia Fernandez, Sanders, Kalina, Satori, Maria, Sazonov, Denis V, Scarpini, Elio Angelo, Schlegel, Eugen, Schluep, Myriam, Schmidt, Stephan, Scholz, Erich, Schrijver, H M, Schwab, Matthias, Schwartz, Raymond, Scott, James, Selmaj, Krzysztof, Shafer, Stuart, Sharrack, Basil, Shchukin, Ivan A, Shimizu, Yuko, Shotekov, Penko, Siever, Arno, Sigel, Karl-Otto, Silliman, Scott, Simo, Magdolna, Simu, Mihaela, Sinay, Vladimiro, Siquier, Antonio Escartin, Siva, Aksel, Skoda, Ondrej, Solomon, Andrew, Stangel, Martin, Stefoski, Dusan, Steingo, Brian, Stolyarov, Igor D, Stourac, Pavel, Strassburger-Krogias, Katrin, Strauss, Erik, Stuve, Olaf, Tarnev, Ivaylo, Tavernarakis, Antonios, Tello, Cristina Ramo, Terzi, Murat, Ticha, Veronika, Ticmeanu, Marina, Tiel-Wilck, Klaus, Toomsoo, Toomas, Tubridy, Niall, Tullman, Mark J, Tumani, Hayrettin, Turcani, Peter, Turner, Ben, Uccelli, Antonio, Urtaza, Francisco Javier Olascoaga, Vachova, Marta, Valikovics, Attila, Walter, Silke, Van Wijmeersch, Bart, Vanopdenbosch, Ludo, Weber, Joerg R, Weiss, Sara, Weissert, Robert, Vermersch, Patrick, West, Timothy, Wiendl, Heinz, Wiertlewski, Sandrine, Wildemann, Brigitte, Willekens, Barbara, Visser, L H, Vorobeychik, Galina, Xu, Xianhao, Yamamura, Takashi, Yang, Yi N, Yelamos, Sergio Martinez, Yeung, Michael, Zacharias, Alan, Zelkowitz, Marvin, Zettl, Uwe, Zhang, Meini, Zhou, Hongyu, Zieman, Ulf, Ziemssen, Tjalf, Kappos, Ludwig, Bar-Or, Amit, Cree, Bruce A C, Fox, Robert J, Giovannoni, Gavin, Gold, Ralf, Arnold, Douglas L, Arnould, Sophie, Scherz, Tatiana, Wolf, Christian, Wallström, Erik, and Dahlke, Frank

Published
2018
Full Text
View/download PDF

14. International Pediatric MS Study Group Clinical Trials Summit

Author

Chitnis, Tanuja, Tardieu, Marc, Amato, Maria Pia, Banwell, Brenda, Bar-Or, Amit, Ghezzi, Angelo, Kornberg, Andrew, Krupp, Lauren B, Pohl, Daniela, Rostasy, Kevin, Tenembaum, Silvia, Waubant, Emmanuelle, and Wassmer, Evangeline

Subjects
Clinical Trials and Supportive Activities, Brain Disorders, Rare Diseases, Pediatric Research Initiative, Neurosciences, Patient Safety, Clinical Research, Multiple Sclerosis, Pediatric, Orphan Drug, Neurodegenerative, Autoimmune Disease, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Clinical Trials as Topic, Consensus Development Conferences as Topic, District of Columbia, Humans, Immunologic Factors, Internationality, Pediatrics, Research Report, Clinical Sciences, Cognitive Sciences, Neurology & Neurosurgery
Abstract

ObjectivePediatric studies for new biological agents are mandated by recent legislation, necessitating careful thought to evaluation of emerging multiple sclerosis (MS) therapies in children with MS. Challenges include a small patient population, the lack of prior randomized clinical trials, and ethical concerns. The goal of this meeting was to assess areas of consensus regarding clinical trial design and outcome measures among academic experts involved in pediatric MS care and research.MethodsThe Steering Committee of the International Pediatric MS Study Group identified key focus areas for discussion. A total of 69 meeting attendees were assembled, including 35 academic experts. Regulatory and pharmaceutical representatives also attended, and provided input, which informed academic expert consensus decisions.ResultsThe academic experts agreed that clinical trials were necessary in pediatric MS to obtain pharmacokinetic, safety and efficacy data, and regulatory approval allowing for greater medication access. The academic experts agreed that relapse was an appropriate primary outcome measure for phase III pediatric trials. An international standardized cognitive battery was identified. The pros and cons of various trial designs were discussed. Guidelines surrounding MRI studies, pharmacokinetics, pharmacodynamics, and registries were developed. The academic experts agreed that given the limited subject pool, a stepwise approach to the launch of clinical trials for the most promising medications is necessary in order to ensure study completion. Alternative approaches could result in unethical exposure of patients to trial conditions without gaining knowledge.ConclusionConsensus points for conduct of clinical trials in the rare disease pediatric MS were identified amongst a panel of academic experts, informed by regulatory and industry stakeholders.

Published
2013

15. Cognitive Impairment Occurs in Children and Adolescents With Multiple Sclerosis

Author

Julian, Laura, Serafin, Dana, Charvet, Leigh, Ackerson, Joseph, Benedict, Ralph, Braaten, Ellen, Brown, Tanya, O’Donnell, Ellen, Parrish, Joy, Preston, Thomas, Zaccariello, Michael, Belman, Anita, Chitnis, Tanuja, Gorman, Mark, Ness, Jayne, Patterson, Marc, Rodriguez, Moses, Waubant, Emmanuelle, Weinstock-Guttman, Bianca, Yeh, Ann, and Krupp, Lauren B

Subjects
Multiple Sclerosis, Neurosciences, Neurodegenerative, Pediatric, Clinical Research, Autoimmune Disease, Brain Disorders, Mental health, Adolescent, Child, Cognition Disorders, Cross-Sectional Studies, Female, Humans, Logistic Models, Male, Nervous System Diseases, Neuropsychological Tests, United States, multiple sclerosis, cognition, clinically isolated syndrome, demyelination, Network of Pediatric MS Centers of Excellence, Clinical Sciences, Cognitive Sciences, Neurology & Neurosurgery
Abstract

In the largest sample studied to date, we measured cognitive functioning in children and adolescents with pediatric multiple sclerosis (n = 187) as well as those with clinically isolated syndrome (n = 44). Participants were consecutively enrolled from six United States Pediatric Multiple Sclerosis Centers of Excellence. Participants had a mean of 14.8 ± 2.6 years of age and an average disease duration of 1.9 ± 2.2 years. A total of 65 (35%) children with multiple sclerosis and 8 (18%) with clinically isolated syndrome met criteria for cognitive impairment. The most frequent areas involved were fine motor coordination (54%), visuomotor integration (50%), and speeded information processing (35%). A diagnosis of multiple sclerosis (odds ratio = 3.60, confidence interval = 1.07, 12.36, P = .04) and overall neurologic disability (odds ratio = 1.47, confidence interval = 1.10, 2.10, P = .03) were the only independent predictors of cognitive impairment. Cognitive impairment may occur early in these patients, and prompt recognition is critical for their care.

Published
2013

16. Multiple Sclerosis Performance Test: Technical Development and Usability

Author

Rhodes, Jane K., Schindler, David, Rao, Stephen M., Venegas, Fernando, Bruzik, Efrosini T., Gabel, Wendy, Williams, James R., Phillips, Glenn A., Mullen, Colleen C., Freiburger, Jaime L., Mourany, Lyla, Reece, Christine, Miller, Deborah M., Bethoux, Francois, Bermel, Robert A., Krupp, Lauren B., Mowry, Ellen M., Alberts, Jay, and Rudick, Richard A.

Published
2019
Full Text
View/download PDF

19. Fatigue

Author

Bhise, Vikram, Krupp, Lauren B., Ferro, José M., Series editor, and Brochet, Bruno, editor

Published
2015
Full Text
View/download PDF

22. Associations of sNfL with clinico‐radiological measures in a large MS population

Author

Sotirchos, Elias S., primary, Fitzgerald, Kathryn C., additional, Singh, Carol M., additional, Smith, Matthew D., additional, Reyes‐Mantilla, Maria, additional, Hersh, Carrie M., additional, Hyland, Megan H., additional, Canissario, Ryan, additional, Simmons, Sarah B., additional, Arrambide, Georgina, additional, Montalban, Xavier, additional, Comabella, Manuel, additional, Naismith, Robert T., additional, Qiao, Min, additional, Krupp, Lauren B., additional, Nicholas, Jacqueline A., additional, Akgün, Katja, additional, Ziemssen, Tjalf, additional, Rudick, Richard, additional, Fisher, Elizabeth, additional, Bermel, Robert A., additional, Mowry, Ellen M., additional, and Calabresi, Peter A., additional

Published
2022
Full Text
View/download PDF

24. Lyme Disease

Author

Halperin, John, primary, Krupp, Lauren B., additional, and Melville, Patricia, additional

Published
2017
Full Text
View/download PDF

25. Fatigue

Author

Christodoulou, Christopher, MacAllister, William S., Krupp, Lauren B., Tarsy, Daniel, editor, Jests, Dilip V., editor, and Friedman, Joseph H., editor

Published
2006
Full Text
View/download PDF

27. Lyme Disease

Author

Krupp, Lauren B., Melville, Patricia, Kreutzer, Jeffrey S., editor, DeLuca, John, editor, and Caplan, Bruce, editor

Published
2011
Full Text
View/download PDF

30. Associations of with clinico-radiological measures in a large population

Author

Sotirchos, Elias S., Fitzgerald, Kathryn, Singh, Carol, Smith, Matthew D., Reyes-Mantilla, Maria, Hersh, Carrie, Hyland, Megan H., Canissario, Ryan, Simmons, Sarah B., Arrambide, Georgina, Montalban, Xavier, Comabella, Manuel, Naismith, Robert, Qiao, Min, Krupp, Lauren B., Nicholas, Jacqueline A., Akgün, Katja, Ziemssen, Tjalf, Rudick, Richard, Fisher, Elizabeth, Bermel, Robert, Mowry, Ellen, Calabresi, Peter A., and Universitat Autònoma de Barcelona

Abstract

Evaluation of serum neurofilament light chain (sNfL), measured using high-throughput assays on widely accessible platforms in large, real-world MS populations, is a critical step for sNfL to be utilized in clinical practice. Multiple Sclerosis Partners Advancing Technology and Health Solutions (MS PATHS) is a network of healthcare institutions in the United States and Europe collecting standardized clinical/imaging data and biospecimens during routine clinic visits. sNfL was measured in 6974 MS and 201 healthy control (HC) participants, using a high-throughput, scalable immunoassay. Elevated sNfL levels for age (sNfL-E) were found in 1238 MS participants (17.8%). Factors associated with sNfL-E included male sex, younger age, progressive disease subtype, diabetes mellitus, impaired renal function, and active smoking. Higher body mass index (BMI) was associated with lower odds of elevated sNfL. Active treatment with disease-modifying therapy was associated with lower odds of sNfL-E. MS participants with sNfL-E exhibited worse neurological function (patient-reported disability, walking speed, manual dexterity, and cognitive processing speed), lower brain parenchymal fraction, and higher T2 lesion volume. Longitudinal analyses revealed accelerated short-term rates of whole brain atrophy in sNfL-E participants and higher odds of new T2 lesion development, although both MS participants with or without sNfL-E exhibited faster rates of whole brain atrophy compared to HC. Findings were consistent in analyses examining age-normative sNfL Z-scores as a continuous variable. Elevated sNfL is associated with clinical disability, inflammatory disease activity, and whole brain atrophy in MS, but interpretation needs to account for comorbidities including impaired renal function, diabetes, and smoking.

Published
2022

32. A new look at cognitive functioning in pediatric MS.

Author

Krupp, Lauren B, Waubant, Emmanuelle, Waltz, Michael, Casper, T Charles, Belman, Anita, Wheeler, Yolanda, Ness, Jayne, Graves, Jennifer, Gorman, Mark, Benson, Leslie, Mar, Soe, Goyal, Manu, Schreiner, Teri, Weinstock-Guttman, Bianca, Rodriguez, Moses, Tillema, Jan-Mendelt, Lotze, Timothy, Aaen, Greg, Rensel, Mary, and Rose, John

Subjects
*COGNITIVE ability, *VERBAL learning, *AUDITORY learning, *MULTIPLE sclerosis, *DISEASE duration
Abstract

Objective: Cognitive involvement in pediatric multiple sclerosis (MS) relative to adult MS is less defined. This study advances our understanding by measuring cognitive performances in pediatric MS, adult MS, and pediatric healthy controls. Methods: Consecutive relapsing pediatric MS participants from the United States Network of Pediatric MS Centers were compared with pediatric healthy controls and adults with relapsing MS. Participants were compared on two screening batteries: the Brief International Cognitive Assessment for MS and the Cogstate Brief Battery. Results were transformed to age-normative z scores. Results: The pediatric groups (MS vs. Healthy Controls) did not differ on either battery's composite mean score or individual test scores (p s > 0.32), nor in the proportions impaired on either battery, Brief International Cognitive Assessment for MS (26% vs. 24%, p = 0.83); Cogstate Brief Battery (26% vs. 32%, p = 0.41). The pediatric versus adult MS group even after controlling for differences in disease duration performed better on the Brief International Cognition Assessment for MS composite (p = 0.03), Symbol Digit Modalities Test (p = 0.02), Rey Auditory Verbal Learning Test (p = 0.01), and Cogstate choice reaction time (p < 0.001). Conclusion: Pediatric MS patients do not differ from healthy pediatric controls on cognitive screens but perform better than adults with MS. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

33. Associations of sNfL with clinico‐radiological measures in a large MS population.

Author

Sotirchos, Elias S., Fitzgerald, Kathryn C., Singh, Carol M., Smith, Matthew D., Reyes‐Mantilla, Maria, Hersh, Carrie M., Hyland, Megan H., Canissario, Ryan, Simmons, Sarah B., Arrambide, Georgina, Montalban, Xavier, Comabella, Manuel, Naismith, Robert T., Qiao, Min, Krupp, Lauren B., Nicholas, Jacqueline A., Akgün, Katja, Ziemssen, Tjalf, Rudick, Richard, and Fisher, Elizabeth

Subjects
COGNITIVE processing speed, CEREBRAL atrophy, WALKING speed, BODY mass index, MOTOR ability, MONOCLONAL gammopathies
Abstract

Objective: Evaluation of serum neurofilament light chain (sNfL), measured using high‐throughput assays on widely accessible platforms in large, real‐world MS populations, is a critical step for sNfL to be utilized in clinical practice. Methods: Multiple Sclerosis Partners Advancing Technology and Health Solutions (MS PATHS) is a network of healthcare institutions in the United States and Europe collecting standardized clinical/imaging data and biospecimens during routine clinic visits. sNfL was measured in 6974 MS and 201 healthy control (HC) participants, using a high‐throughput, scalable immunoassay. Results: Elevated sNfL levels for age (sNfL‐E) were found in 1238 MS participants (17.8%). Factors associated with sNfL‐E included male sex, younger age, progressive disease subtype, diabetes mellitus, impaired renal function, and active smoking. Higher body mass index (BMI) was associated with lower odds of elevated sNfL. Active treatment with disease‐modifying therapy was associated with lower odds of sNfL‐E. MS participants with sNfL‐E exhibited worse neurological function (patient‐reported disability, walking speed, manual dexterity, and cognitive processing speed), lower brain parenchymal fraction, and higher T2 lesion volume. Longitudinal analyses revealed accelerated short‐term rates of whole brain atrophy in sNfL‐E participants and higher odds of new T2 lesion development, although both MS participants with or without sNfL‐E exhibited faster rates of whole brain atrophy compared to HC. Findings were consistent in analyses examining age‐normative sNfL Z‐scores as a continuous variable. Interpretation: Elevated sNfL is associated with clinical disability, inflammatory disease activity, and whole brain atrophy in MS, but interpretation needs to account for comorbidities including impaired renal function, diabetes, and smoking. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

35. List of contributors

Author

Abell, Thomas, Acosta, Camilo J., Adadey, Samuel Mawuli, Anaya, Juan-Manuel, Annibale, Bruno, Antonini, Simone, Aqeel, Faten, Arepalli, Sruthi, Assassi, Shervin, Babushok, Daria V., Barkin, Jodie A., Bartalena, Luigi, Ben Nasr, Moufida, Berentsen, Sigbjørn, Betterle, Corrado, Birtolo, Maria Francesca, Bisarya, Pooja Nikki, Blüml, Stephan, Bonomi, Marco, Bowlus, Christopher L., Brassard, Alain, Brusch, Anna, Burrone, Marco, Carrillo-Bayona, Jorge Alberto, Casciola-Rosen, Livia, Caturegli, Patrizio, Chang, Christopher, Chatzis, Loukas, Chaves, Juan José, Chen, Dhruti P., Chen, Jingjing, Chen, Saijuan, Cheng, Wenyan, Chhabra, Garvit, Choi, Jamie H., Cianferotti, Luisella, Crowell, Eric, Cuda, Carla M., Davidson, Anne, Deane, Sean, del Carmen Moleon, Maria, Di Dalmazi, Giulia, Dilaghi, Emanuele, Dixon Johns, James, Doost, Mohammad Saffari, Dyke, Jason, D’Addio, Francesca, D’Cruz, David P., Falk, Ronald J., Farina, Antonio, Fattizzo, Bruno, Fernandez-Carbonell, Cristina, Fiorina, Paolo, Flanagan, Eoin P., Franzen, Daniel P., Frederiksen, Henrik, Free, Meghan E., Frejo, Lidia, Fung, Maxwell A., Gaffney, Patrick M., Galindo, Javier Leonardo, Gallo, Daniela, Gately, Ursula, Geetha, Duvuru, Gershwin, M. Eric, Goldbach-Mansky, Raphaela, Goronzy, Jörg J., Goules, Andreas V., Gudjonsson, Johann E., Guilherme, Luiza, Guo, Weinan, Hajj-Ali, Rula A., Hamburger, Nicole, He, Liting, Herrán, María, Hoa, Michael, Honnorat, Jérôme, Hu, Qingjie, Hu, Yue, Husebye, Eystein S., Ippolito, Silvia, James, Eddie A., James, Judith A., Jennette, J. Charles, Jian, Zhe, Jiang, Ying, Kaklamanos, Aimilios, Kalil, Jorge, Kaminski, Henry J., Kammeyer, Ryan, Kaya, Ziya, Kelly, Jennifer A., Khakoo, Nidah Shabbir, Khoury, Samia J., Kolios, Antonios G.A., Königs, Christoph, Kopplin, Laura J., Krupp, Lauren B., Kuker, Russ, Kwapnoski, Zachary, Kyttaris, Vasileios C., La Cava, Antonio, Lahner, Edith, Lania, Andrea G., Lehmann, Helmar C., Levy, Cynthia, Li, Chunying, Li, Kun, Li, Shuli, Li, Xiangqian, Liu, Hui, Liu, Ling, Liu, Yudong, Lleo, Ana, Long, Hai, Lopez-Escamez, Jose A., Lu, Qianjin, Lunati, Maria Elena, Lunn, Michael P.T., Lupi, Isabella, Malattia, Clara, Maletic-Savatic, Mirjana, Marietta, Eric V., Martin, Cole, Martini, Alberto, Mastaglia, Frank, Mathur, Prateek, Mazziotti, Gherardo, McDonald, Benjamin, Mehta, Neesurg S., Mieli-Vergani, Giorgina, Milano, Reza V., Morel, Laurence, Moss, Brandon, Moussa, Kareem, Murray, Joseph A., Naing, LeYu, Needham, Merrilee, Nelson, Andrew J., Nilsson, Jakob, O'Neill, Kimberly A., Ochoa, Jorge R., Öztosun, Gülşen, Pan, Meng, Paramalingam, Shereen, Pathak, Shresh, Pei, Chenchen, Perl, Andras, Perlman, Harris, Persani, Luca, Pillai, Shiv, Piquet, Amanda L., Poddubnyy, Denis, Polo, Fernando, Presotto, Fabio, Rabb, Hamid, Radin, Massimo, Rochat, Pete, Rodolfi, Stefano, Rojas, Manuel, Rosen, Antony, Rossetti, Raffaella, Rubin, David T., Saab, Georges, Sabbadin, Chiara, Salbach, Christian, Schreiber, Karen, Sciascia, Savino, Sheikh, Kazim A., Shen, Yang, Shusko, Alexander R., Sieper, Joachim, Smilek, Dawn Elaine, Smith, Kenneth, Smolen, Josef S., Sorkhabi, Sharareh Yousefpour, Stocker, Abigail, Stone, John H., Stroikova, Vera, Sun, Yonghu, Syrbe, Uta, Tanda, Maria Laura, Taubenslag, Kenneth J., Terziroli Beretta-Piccoli, Benedetta, Tessneer, Kandice L., Thakolwiboon, Smathorn, Tian, Jingru, Tiniakou, Eleni, Titulaer, Maarten J., Tsui, Edmund, Tzioufas, Athanasios G., Vambutas, Andrea, van Steenhoven, Robin W., Varga, John, Vergani, Diego, Villagrán-García, Macarena, Vondenberg, Jaime A., Vora, Paras, Wagner, Catriona A., Wang, Gang, Wang, Jingying, Wang, Min, Wang, Xin, Weinstein, Jessica E., Weyand, Cornelia M., Xin, Yue, Xing, Enze, Yao, Xu, Yu, Cong, Zhang, Furen, Zhang, Jianzhong, Zhang, Xuan, Zhou, Cheng, Zhu, Haiqin, Zhu, Hong, Zinger, Adar, and Zuo, Xiaoxia

Published
2024
Full Text
View/download PDF

42. No difference in radiologic outcomes for natalizumab patients on extended interval dosing compared with standard interval dosing in MS PATHS (1964)

Author

Ryerson, Lana Zhovtis, primary, Naismith, Robert T., additional, Krupp, Lauren B., additional, Charvet, Leigh, additional, Liao, Shirley, additional, Fisher, Elizabeth, additional, De Moor, Carl, additional, Williams, James R., additional, Licata, Stephanie, additional, and Campbell, Nolan, additional

Published
2021
Full Text
View/download PDF

43. Aucune différence relevée en termes d’activité radiologique entre les patients traités par natalizumab en administration à intervalles prolongés (EID) par rapport à l’administration à intervalles standard (SID) dans MS PATHS

Author

Ryerson, Lana Zhovtis, primary, Naismith, Robert T., additional, Krupp, Lauren B., additional, Charvet, Leigh E., additional, Su, Ray, additional, Fisher, Elizabeth, additional, De Moor, Carl, additional, Williams, James R., additional, and Campbell, Nolan, additional

Published
2021
Full Text
View/download PDF

45. COVID-19 outcomes in MS

Author

Parrotta, Erica, Kister, Ilya, Charvet, Leigh, Sammarco, Carrie, Saha, Valerie, Charlson, Robert Erik, Howard, Jonathan, Gutman, Josef Maxwell, Gottesman, Malcolm, Abou-Fayssal, Nada, Wolintz, Robyn, Keilson, Marshall, Fernandez-Carbonell, Cristina, Krupp, Lauren B., and Zhovtis Ryerson, Lana

Subjects
Article
Abstract

Objective To report outcomes on patients with multiple sclerosis (MS) and related disorders with coronavirus disease 2019 (COVID-19) illness. Methods From March 16 to April 30, 2020, patients with MS or related disorders at NYU Langone MS Comprehensive Care Center were identified with laboratory-confirmed or suspected COVID-19. The diagnosis was established using a standardized questionnaire or by review of in-patient hospital records. Results We identified 76 patients (55 with relapsing MS, of which 9 had pediatric onset; 17 with progressive MS; and 4 with related disorders). Thirty-seven underwent PCR testing and were confirmed positive. Of the entire group, 64 (84%) patients were on disease-modifying therapy (DMT) including anti-CD20 therapies (n = 34, 44.7%) and sphingosine-1-phosphate receptor modulators (n = 10, 13.5%). The most common COVID-19 symptoms were fever and cough, but 21.1% of patients had neurologic symptom recrudescence preceding or coinciding with the infection. A total of 18 (23.7%) were hospitalized; 8 (10.5%) had COVID-19 critical illness or related death. Features more common among those hospitalized or with critical illness or death were older age, presence of comorbidities, progressive disease, and a nonambulatory status. No DMT class was associated with an increased risk of hospitalization or fatal outcome. Conclusions Most patients with MS with COVID-19 do not require hospitalization despite being on DMTs. Factors associated with critical illness were similar to the general at-risk patient population. DMT use did not emerge as a predictor of poor COVID-19 outcome in this preliminary sample.

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results